重组人白介素-11与重组人促血小板生成素治疗化疗相关血小板减少的疗效比较
|
摘要
目的比较重组人白细胞介素-11(rh IL-11)与重组人促血小板生成素(rh TPO)治疗肺癌患者化疗相关血小板减少症的临床疗效。方法采用回顾性分析法,收集2015年1月~2015年8月化疗导致血小板减少而使用rh IL-11或rh TPO的肺癌患者40例,比较两种药物治疗化疗相关血小板减少的疗效。结果 rh IL-11组、rh TPO组血小板开始恢复时间分别为4.79±3.87d和4.95±3.44d,达标时间分别为8.50±4.17d和8.81±4.26d,均无统计学差异(P值均>0.05);血小板升至100×109·L-1或较原水平上升50×109·L-1以上的患者,rh IL-11组有13例(68.42%),rh TPO组为14例(66.67%),均无统计学差异(P值均>0.05)。结论 rh TPO和rh IL-11治疗化疗相关血小板减少的疗效无显著性差异。
OBJECTIVE To compare the clinical effect between rh IL-11 and rh TPO on treatment for lung cancer patients with thrombocytopenia. METHODS A retrospective analysis was uesd. Total 40 lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rh IL-11 or rh TPO from January2015 to August 2015 were involved in the study,and the efficacy were evaluated and compared. RESULTS The time of platelet count beginning to recover was 4. 79 ± 3. 87 d in rh IL-11 group and 4. 95 ± 3. 44 d in rh TPO group( P> 0. 05). The duration of thrombocytopenia was 8. 50 ± 4. 17 d in rh IL-11 group and 8. 81 ± 4. 26 d in rh TPO group( P > 0. 05). There were 13 patients in rh IL-11 group and 14 patients in rh TPO group whose platelet count increased above 100 × 109·L- 1or 50 × 109·L- 1more than previous level after therapy( P > 0. 05). CONCLUSION There was not differences between rh TPO and rh IL-11 on treatment for lung cancer patients with thrombocytopenia.
OBJECTIVE To compare the clinical effect between rh IL-11 and rh TPO on treatment for lung cancer patients with thrombocytopenia. METHODS A retrospective analysis was uesd. Total 40 lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rh IL-11 or rh TPO from January2015 to August 2015 were involved in the study,and the efficacy were evaluated and compared. RESULTS The time of platelet count beginning to recover was 4. 79 ± 3. 87 d in rh IL-11 group and 4. 95 ± 3. 44 d in rh TPO group( P> 0. 05). The duration of thrombocytopenia was 8. 50 ± 4. 17 d in rh IL-11 group and 8. 81 ± 4. 26 d in rh TPO group( P > 0. 05). There were 13 patients in rh IL-11 group and 14 patients in rh TPO group whose platelet count increased above 100 × 109·L- 1or 50 × 109·L- 1more than previous level after therapy( P > 0. 05). CONCLUSION There was not differences between rh TPO and rh IL-11 on treatment for lung cancer patients with thrombocytopenia.
引文
[1]张凤华,杨东.血小板变化在临床中的应用[J].中华临床医学研究杂志,2008,14(1):42.
[2]郭庆东,戴月娥,穆士杰,等.血小板输注治疗血液病79例患者的效果[J].第四军医大学学报,2002,23(7):651-652.
[3]白春梅,徐光勋,赵水强,等.重组人血小板生成素治疗实体瘤患者化疗后血小板减少的多中心临床试验[J].中国医学科学院学报,2004,26(4):437-441.
[4]徐云华,陈智伟,叶翔赟,等.重组人血小板生成素治疗肺癌患者化疗后血小板减少的临床观察[J].中华肿瘤杂志,2008,30(9):716-719.
[5]曹君宁,许立功,吴晴,等.重组人白介素-11治疗化疗引起的血小板减少症的Ⅱ期临床研究[J].中国癌症杂志,2005,15(2):141-144.
[6]王兴元,冯奉仪,宋三泰,等.国产重组人白介素-11衍生物治疗化疗所致血小板降低的多中心临床研究[J].中华肿瘤杂志,2005,27(6):373-376.
[7]Kaushansky K.Thrombopoietin[J].N Engl J Med,1998,339(11):746-754.
[8]喻杰,戴晓芳,刘莉,等.rh TPO和IL-11治疗NSCLC化疗后血小板减少症的临床观察[J].中华肿瘤防治杂志,2009,16(5):374-376.
[9]陈坚,瞿琴,魏燕,等.重组人促血小板生成素与重组人白细胞介素-11治疗肿瘤患者血小板减少症的疗效比较[J].实用肿瘤杂志,2010,25(3):318-320.
[2]郭庆东,戴月娥,穆士杰,等.血小板输注治疗血液病79例患者的效果[J].第四军医大学学报,2002,23(7):651-652.
[3]白春梅,徐光勋,赵水强,等.重组人血小板生成素治疗实体瘤患者化疗后血小板减少的多中心临床试验[J].中国医学科学院学报,2004,26(4):437-441.
[4]徐云华,陈智伟,叶翔赟,等.重组人血小板生成素治疗肺癌患者化疗后血小板减少的临床观察[J].中华肿瘤杂志,2008,30(9):716-719.
[5]曹君宁,许立功,吴晴,等.重组人白介素-11治疗化疗引起的血小板减少症的Ⅱ期临床研究[J].中国癌症杂志,2005,15(2):141-144.
[6]王兴元,冯奉仪,宋三泰,等.国产重组人白介素-11衍生物治疗化疗所致血小板降低的多中心临床研究[J].中华肿瘤杂志,2005,27(6):373-376.
[7]Kaushansky K.Thrombopoietin[J].N Engl J Med,1998,339(11):746-754.
[8]喻杰,戴晓芳,刘莉,等.rh TPO和IL-11治疗NSCLC化疗后血小板减少症的临床观察[J].中华肿瘤防治杂志,2009,16(5):374-376.
[9]陈坚,瞿琴,魏燕,等.重组人促血小板生成素与重组人白细胞介素-11治疗肿瘤患者血小板减少症的疗效比较[J].实用肿瘤杂志,2010,25(3):318-320.